| Nanobiotix to Participate in the H.C. Wainwright 3rd Annual BioConnect Investor Conference at NASDAQ |
PARIS and CAMBRIDGE, Mass., May 12, 2025 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company''), a late-clinical stage biotechnology company pioneering nanoparticle-based approaches to expand treatment possibilities for patients with cancer and other major diseases, announced today that Company management will participate in fireside chats at following conference: |
globenewswire.com |
2025-05-12 06:00:00 |
Czytaj oryginał (ang.) |
| Nanobiotix Announces Full Results From Completed Phase 1 Study Evaluating JNJ-1900 (NBTXR3) in Pancreatic Cancer |
Results demonstrated favorable safety, injection feasibility, and encouraging oncologic outcomes in patients (n=22) with locally advanced or borderline resectable pancreatic cancer Median Overall Survival of 23 months from date of diagnosis [95% CI; 17 months – not reached] Median Local Progression-Free Survival of 13.3 months from completion of radiation Notable findings observed in exploratory biomarker analyses include: An association between increased circulating tumor mutational burden (cTMB) and LPFS and OS CA19-9 normalization in 59% of patients in the study, and an association between CA19-9 normalization and OS First patient injected in a new cohort that adds standard-of-care concurrent chemotherapy (capecitabine or 5-FU) to radiotherapy-activated JNJ-1900 (NBTXR3) and recruitment is ongoing Investigators concluded that these results support further evaluation in a randomized study Data presented at the 2025 Annual Meeting of the European Society of Radiation Oncology PARIS and CAMBRIDGE, Mass., May 05, 2025 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company''), a late-stage clinical biotechnology company pioneering nanotherapeutic approaches to improve treatment outcomes for patients with cancer, today announced the presentation of full results from the completed dose escalation and dose expansion phases of a Phase 1 study evaluating JNJ-1900 (NBTXR3) in patients with locally advanced or borderline resectable pancreatic cancer. |
globenewswire.com |
2025-05-05 06:00:00 |
Czytaj oryginał (ang.) |
| Nanobiotix Announces Presentation of Full Results From Completed Phase 1 Study Evaluating JNJ-1900 (NBTXR3) in Pancreatic Cancer Followed by a Conference Call |
PARIS and CAMBRIDGE, Mass., April 30, 2025 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company''), a late-clinical stage biotechnology company pioneering nanoparticle-based therapeutic approaches to expand treatment possibilities for patients with cancer and other major diseases, today announced the presentation of full results from the completed dose escalation and dose expansion parts of a Phase 1 study evaluating JNJ-1900 (NBTXR3) in patients with locally advanced or borderline resectable pancreatic cancer. The study, conducted by The University of Texas MD Anderson Cancer Center, will be presented by principal investigator Dr. Eugene Koay on Sunday, May 4th at 11:00 AM EDT / 5:00 PM CEST during the 2025 Annual Meeting of the European Society for Radiotherapy and Oncology (ESTRO 2025). |
globenewswire.com |
2025-04-30 06:00:00 |
Czytaj oryginał (ang.) |
| Nanobiotix S.A. (NBTX) Q4 2024 Earnings Call Transcript |
Nanobiotix S.A. (NASDAQ:NBTX ) Q4 2024 Results Conference Call April 3, 2025 8:00 AM ET Company Participants Craig West - Senior Vice President, Investor Relations Laurent Levy - Co-Founder and Chief Executive Officer Bart Van Rhijn - Chief Financial and Business Officer Conference Call Participants Yen-Der Li - Leerink Partners Shan Hama - Jefferies Michael Schmidt - Guggenheim Securities Art He - HCW David Dai - UBS Operator Good day, and welcome to the Nanobiotix Business Update and Full Year 2024 Financial Results Conference Call. |
seekingalpha.com |
2025-04-03 20:24:01 |
Czytaj oryginał (ang.) |
| NANOBIOTIX Provides Business Update and Reports Full Year 2024 Financial Results |
Global development program for JNJ-1900 (NBTXR3) proceeding as planned, with opportunity to address one of the largest untapped markets in oncology through lead programs in head and neck cancer and lung cancer Disciplined financial strategy toward long-term sustainability and growth continues to strengthen financial position through focused allocation of capital, the receipt of a planned milestone payment, the transfer of sponsorship for NANORAY-312, and an amendment to the global licensing agreement for JNJ-1900 (NBTXR3) Curadigm, a next generation nanotherapeutic platform designed to reshape drug design and development across multiple therapeutic classes and disease areas, has launched Cash runway extended into mid-2026 and reduction of operational cash burn expected beyond mid-2026 with €49.7 million in cash and cash equivalents as of December 31, 2024 Clinical data readouts in 2025 from Phase 1 and 2 studies in RM-HNSCC, pancreatic cancer, NSCLC amenable to re-irradiation, melanoma and esophageal cancer Conference call and webcast scheduled for April 3, 2025 at 8:00 A.M. EDT / 2:00 P.M. |
globenewswire.com |
2025-04-02 20:15:00 |
Czytaj oryginał (ang.) |
| NANOBIOTIX to Announce Fourth Quarter and Full Year 2024 Operational and Financial Update on April 2, 2025 |
Conference call and webcast scheduled for Thursday, April 3, 2025, at 8:00 am EDT / 2:00 pm CEST Conference call and webcast scheduled for Thursday, April 3, 2025, at 8:00 am EDT / 2:00 pm CEST |
globenewswire.com |
2025-03-31 06:00:00 |
Czytaj oryginał (ang.) |
| Nanobiotix Announces First Data From the Completed Dose Escalation Part of a Phase 1 Study Evaluating NBTXR3 (JNJ-1900) as a 2L+ Therapy for Patients With Locally Advanced NSCLC |
PARIS and CAMBRIDGE, Mass., March 27, 2025 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company''), a late-stage clinical biotechnology company pioneering disruptive, nanotherapeutic approaches to revolutionize treatment outcomes for millions of patients, today announced the first data from the completed dose escalation part of a Phase 1 study sponsored by The University of Texas MD Anderson Cancer Center ("MD Anderson") evaluating radiotherapy-activated NBTXR3 (JNJ-1900)1 as a second or later line (2L+) therapy for patients with locally advanced non-small cell lung cancer (“NSCLC”) amenable to re-irradiation. These data will be presented at the 2025 European Lung Cancer Conference by study principal investigator Dr. Saumil Gandhi. |
globenewswire.com |
2025-03-27 18:15:00 |
Czytaj oryginał (ang.) |
| NANOBIOTIX Announces Presentation of Data From Two Phase 1 Studies Evaluating JNJ-1900 (NBTXR3) at the European Lung Cancer Conference |
PARIS and CAMBRIDGE, Mass., March 20, 2025 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company''), a late-clinical stage biotechnology company pioneering nanoparticle-based therapeutic approaches to expand treatment possibilities for patients with cancer and other major diseases, today announced poster presentations from two Phase 1 studies evaluating JNJ-1900 (NBTXR3) for patients with lung cancer (NSCLC) to be presented at the 2025 European Lung Cancer Conference (“ELCC”). |
globenewswire.com |
2025-03-20 18:15:00 |
Czytaj oryginał (ang.) |
| NANOBIOTIX Strengthens Financial Position Through Amendment of Global Licensing Agreement for JNJ-1900 (NBTXR3) and Extends Cash Visibility to Mid-2026 |
Conference call and webcast scheduled for March 18, 2025, at 8:30 A.M. EDT / 1:30 P.M. CET Conference call and webcast scheduled for March 18, 2025, at 8:30 A.M. EDT / 1:30 P.M. CET |
globenewswire.com |
2025-03-17 18:15:00 |
Czytaj oryginał (ang.) |
| Nanobiotix to Participate in Multiple Investor Conferences in February and March 2025 |
PARIS and CAMBRIDGE, Mass., Jan. 29, 2025 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company''), a late-clinical stage biotechnology company pioneering nanoparticle-based approaches to expand treatment possibilities for patients with cancer and other major diseases, announced today that Company management will participate in fireside chats at following conferences: |
globenewswire.com |
2025-01-29 18:15:00 |
Czytaj oryginał (ang.) |
| Nanobiotix Stock Gains as Dosing Begins in Mid-Stage NSCLC Study |
NBTX stock rises following initiation of dosing in a mid-stage NSCLC study evaluating a potential first-in-class radioenhancer, JNJ-1900. |
zacks.com |
2025-01-21 13:46:15 |
Czytaj oryginał (ang.) |
| NANOBIOTIX Announces First Patient Dosed in a New Randomized Phase 2 Study Evaluating JNJ-1900 (NBTXR3) for Patients With Stage 3 Unresectable Non-Small Cell Lung Cancer |
PARIS and CAMBRIDGE, Mass., Jan. 21, 2025 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company''), a late-clinical stage biotechnology company pioneering nanoparticle-based therapeutic approaches to expand treatment possibilities for patients with cancer and other major diseases, today announced that the first patient has been dosed in the CONVERGE study, a Phase 2 randomized controlled clinical trial evaluating potential first-in-class radioenhancer JNJ-1900 (NBTXR3) for the treatment of patients with Stage 3 unresectable non-small cell lung cancer receiving standard of care chemoradiation followed by consolidation durvalumab (NCT06667908). CONVERGE is sponsored by Janssen Pharmaceutica NV, a Johnson & Johnson Company, under a global license agreement. |
globenewswire.com |
2025-01-21 04:30:00 |
Czytaj oryginał (ang.) |
| NANOBIOTIX to Introduce Vision for Transforming Drug Design and Development with Next Nanotherapeutic Platform on 19 December 2024 |
PARIS and CAMBRIDGE, Mass., Dec. 17, 2024 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company''), a late-clinical stage biotechnology company pioneering nanoparticle-based therapeutic approaches to expand treatment possibilities for patients with cancer and other major diseases, today announced a virtual event titled "Accelerating the Future of Nanotherapeutics," scheduled to take place at 9:00 AM ET / 3:00 PM CET on Thursday, December 19, 2024. |
globenewswire.com |
2024-12-17 18:15:00 |
Czytaj oryginał (ang.) |
| NANOBIOTIX Announces Completion of Phase 1 Study of NBTXR3 (JNJ-1900) in Pancreatic Cancer |
PARIS and CAMBRIDGE, Mass., Dec. 09, 2024 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company''), a late-clinical stage biotechnology company pioneering nanoparticle-based therapeutic approaches to expand treatment possibilities for patients with cancer and other major diseases, today announced the completion of the dose escalation and dose expansion parts of a Phase 1 study evaluating radiotherapy(“RT”)-activated NBTXR3 (JNJ-1900) for patients with locally advanced pancreatic cancer (“LAPC”) or borderline resectable pancreatic cancer (“BRPC”). The Phase 1 study is being conducted by The University of Texas MD Anderson Cancer Center (“MD Anderson”). |
globenewswire.com |
2024-12-09 18:15:00 |
Czytaj oryginał (ang.) |
| NANOBIOTIX Provides Third Quarter 2024 Update and Progress on Nanotherapeutics Platforms |
PARIS and CAMBRIDGE, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO - NASDAQ: NBTX - the “Company”), a late-clinical stage biotechnology company pioneering nanoparticle-based approaches to expand treatment possibilities for patients with cancer and other major diseases, provided an update on operational progress and reported financial results for the third quarter of 2024. |
globenewswire.com |
2024-11-12 04:30:00 |
Czytaj oryginał (ang.) |
| NANOBIOTIX to Participate in Multiple Investor Conferences in November |
~ Guggenheim's Inaugural Healthcare Innovation Conference, Nov 11-13 ~ ~ Stifel Healthcare Conference, Nov 18-19 ~ ~ Jefferies London Healthcare Conference, Nov 19-21 ~ PARIS and CAMBRIDGE, Mass., Oct. 31, 2024 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company''), a late-clinical stage biotechnology company pioneering nanoparticle-based approaches to expand treatment possibilities for patients with cancer and other major diseases, announced today that Company management will participate in fireside chats at following conferences: Guggenheim's Inaugural Healthcare Innovation Conference Date: Monday, November 11, 2024Time: 4pm ET / 10pm CETLocation: Boston, MAPresenters: Laurent Levy, Chief Executive Officer of Nanobiotix and Bart van Rhijn, Chief Financial & Business Officer of NanobiotixWebcast link: Click here Stifel Healthcare Conference Date: Monday, November 18, 2024Time: 4:45pm ET / 10:45pm CETLocation: New York, NYPresenter: Bart van Rhijn, Chief Financial & Business Officer of NanobiotixWebcast link: Click here Jefferies London Healthcare Conference Date: Wednesday, November 20, 2024Time: 1pm GMT / 8am ET / 2pm CETLocation: London, UKPresenters: Laurent Levy, Chief Executive Officer of Nanobiotix and Bart van Rhijn, Chief Financial & Business Officer of NanobiotixWebcast link: Click here The fireside chats will be webcast live from the events page of the Investors section of the Company's website. |
globenewswire.com |
2024-10-31 05:30:00 |
Czytaj oryginał (ang.) |
| NANOBIOTIX Provides Business Update and Reports Half Year 2024 Financial Results |
PARIS and CAMBRIDGE, Mass., Sept. 18, 2024 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO - NASDAQ: NBTX - the “Company”), a late-clinical stage biotechnology company pioneering nanoparticle-based approaches to expand treatment possibilities for patients with cancer and other major diseases, provided an update on operational progress and announced its half year financial results for the six-month period ended June 30, 2024. |
globenewswire.com |
2024-09-18 20:15:00 |
Czytaj oryginał (ang.) |
| NANOBIOTIX Announces Two Key Supervisory Board Additions Intended to Further Equip the Company for Sustainable Long-Term Growth |
PARIS and CAMBRIDGE, Mass., Sept. 04, 2024 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company''), a late-clinical stage biotechnology company pioneering nanoparticle-based therapeutic approaches to expand treatment possibilities for patients with cancer and other major diseases, today announced the nominations of Dr. Margaret A. Liu and Ms. Anat Naschitz as observers to its Supervisory Board. |
globenewswire.com |
2024-09-04 20:15:00 |
Czytaj oryginał (ang.) |
| Nanobiotix to Present at H.C. Wainwright 26th Annual Global Investment Conference |
PARIS and CAMBRIDGE, Mass., Sept. 03, 2024 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company''), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, announced today that Company management will participate in a fireside chat at the upcoming H.C. Wainwright 26th Annual Global Investment conference. Please see below for details of the event. |
globenewswire.com |
2024-09-03 20:15:00 |
Czytaj oryginał (ang.) |
| NANOBIOTIX to Host Virtual KOL Event Discussing Potential of NBTXR3 Combined With Immunotherapy in Head and Neck Cancer and Beyond on June 18, 2024 |
PARIS and CAMBRIDGE, Mass., June 12, 2024 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company''), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today announced that it will host a virtual KOL (Key Opinion Leader) event Tuesday June 18, 2024 at 9:00-10:30AM EDT / 3:00-4:30PM CEST. |
globenewswire.com |
2024-06-12 20:15:00 |
Czytaj oryginał (ang.) |
| Nanobiotix Announces New Data Showing Disease Control and Tumor Response in Patients Treated With RT-Activated NBTXR3 Followed By anti-PD-1 For 2l+ R/M HNSCC Naïve or Resistant to Prior anti-PD-1 Therapy |
PARIS and CAMBRIDGE, Mass., June 02, 2024 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company''), a late-clinical stage biotechnology company pioneering nanoparticle-based therapeutic approaches to expand treatment possibilities for patients with cancer and other major diseases, today announced new data from Study 1100, a US Phase 1 dose escalation and dose expansion study evaluating radiotherapy-activated NBTXR3 followed by anti-PD-1 immune checkpoint inhibitors (“ICIs”) as a second-or-later line (“2L+”) therapy for patients with advanced solid and metastatic tumors. These data were presented by Study 1100 Coordinating Investigator Colette Shen, MD, PhD, at the 2024 Annual Meeting of the American Society for Clinical Oncology (“ASCO 2024”). |
globenewswire.com |
2024-06-02 14:00:00 |
Czytaj oryginał (ang.) |
| NANOBIOTIX Announces Presentation of new Data From Phase 1 Immunotherapy Program at the 2024 Annual Meeting of the American Society for Clinical Oncology Followed by an Investor Conference Call |
PARIS and CAMBRIDGE, Mass., May 28, 2024 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company''), a late-clinical stage biotechnology company pioneering nanoparticle-based therapeutic approaches to expand treatment possibilities for patients with cancer and other major diseases, today announced the presentation of updated data from the completed dose escalation part and first data from the ongoing expansion part of Study 1100, a US Phase 1 study evaluating NBTXR3 followed by anti-PD-1 in patients with recurrent or metastatic head and neck cancer (n=68) at the 2024 Annual Meeting of the American Society for Clinical Oncology. The data will be presented by Study 1100 Coordinating Investigator Colette Shen, MD, PhD, during a poster presentation session that begins at 10:00 AM EDT / 4:00 PM CEST on Sunday, June 2nd, 2024. |
globenewswire.com |
2024-05-28 20:15:00 |
Czytaj oryginał (ang.) |
| NANOBIOTIX to Present at the Jefferies Global Healthcare Conference |
PARIS and CAMBRIDGE, Mass., May 23, 2024 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company''), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, announced today that Company management will participate in a fireside chat at the upcoming Jefferies Global Healthcare Conference. Please see below for details of the event. |
globenewswire.com |
2024-05-23 20:15:00 |
Czytaj oryginał (ang.) |
| Nanobiotix S.A. (NBTX) Q1 2024 Earnings Call Transcript |
Nanobiotix S.A. (NASDAQ:NBTX ) Q1 2024 Earnings Conference Call May 22, 2024 8:00 AM ET Company Participants Craig West - SVP, IR Laurent Levy - Co-Founder and CEO Bart Van Rhijn - CFO Conference Call Participants Jonathan Chang - Leerink Partners Lucy Codrington - Jefferies Chiara Montironi - Van Lanschot Kempen Swayampakula Ramakanth - H.C. |
seekingalpha.com |
2024-05-23 00:32:13 |
Czytaj oryginał (ang.) |
| NANOBIOTIX Provides First Quarter 2024 Operational and Financial Update |
PARIS and CAMBRIDGE, Mass., May 22, 2024 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company''), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today provided an update on operational progress and reported financial results for the first quarter of 2024. |
globenewswire.com |
2024-05-22 06:00:00 |
Czytaj oryginał (ang.) |
| Nanobiotix Announces Progress in Global NBTXR3 Development Collaboration Highlighting Robust Pipeline and Pathway to Long-Term Growth |
PARIS and CAMBRIDGE, Mass., May 21, 2024 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext : NANO –– NASDAQ: NBTX – the ‘‘Company''), a late-clinical stage biotechnology company pioneering nanoparticle-based therapeutic approaches to expand treatment possibilities for patients with cancer and other major diseases, today announced updates to its corporate strategy designed to enable long-term growth in view of significant progress in the Company's collaboration for the co-development and global commercialization of lead therapeutic candidate NBTXR3. |
globenewswire.com |
2024-05-21 20:15:00 |
Czytaj oryginał (ang.) |
| NANOBIOTIX to Announce First Quarter Operational and Financial Update on May 22, 2024 |
Conference call and webcast scheduled on May 22, 2024, at 8:00 am EDT / 2:00 pm CEST Conference call and webcast scheduled on May 22, 2024, at 8:00 am EDT / 2:00 pm CEST |
globenewswire.com |
2024-05-15 20:15:00 |
Czytaj oryginał (ang.) |
| NANOBIOTIX Announces US FDA Protocol Acceptance for New Randomized Phase 2 Study Evaluating NBTXR3 for Patients with Stage Three Lung Cancer |
PARIS and CAMBRIDGE, Mass., May 14, 2024 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company''), a late-clinical stage biotechnology company pioneering nanoparticle-based therapeutic approaches to expand treatment possibilities for patients with cancer and other major diseases, today announced that the U.S. Food and Drug Administration (“US FDA”) issued a Study May Proceed Letter for a randomized Phase 2 study evaluating NBTXR3 for the treatment of patients with stage 3, unresectable non-small cell lung cancer (“NSCLC”). An IND to support this trial was submitted by the global trial sponsor, Johnson & Johnson Enterprise Innovation Inc., a Johnson & Johnson company. |
globenewswire.com |
2024-05-14 20:15:00 |
Czytaj oryginał (ang.) |
| Nanobiotix S.A. (NBTX) Q4 2023 Earnings Call Transcript |
Nanobiotix S.A. (NASDAQ:NBTX ) Q4 2023 Earnings Conference Call April 25, 2024 8:00 AM ET Company Participants Craig West - Senior Vice President, Investor Relations Laurent Levy - Co-Founder and Chief Executive Officer Bart Van Rhijn - Chief Financial Officer Conference Call Participants Dylan Drakes - Leerink Partners Lucy Codrington - Jefferies Swayampakula Ramakanth - H.C. |
seekingalpha.com |
2024-04-27 15:51:09 |
Czytaj oryginał (ang.) |
| NANOBIOTIX Provides Business Update and Reports Full Year 2023 Financial Results |
Global licensing, co-development, and commercialization agreement with Janssen Pharmaceutica NV (“Janssen”) expands worldwide potential of novel radioenhancer NBTXR3 Prolonged survival in Study 102 reinforces pivotal NANORAY-312 trial design in head and neck cancer; initial efficacy and favorable safety profile supports potential of NBTXR3 in pancreatic cancer; determined RP2D for MD Anderson lung study Multiple clinical readouts expected in 2024 including immunotherapy combination data from Study 1100, and data from MD Anderson program €75.3 million in cash and cash equivalents as of December 31, 2023 with cash runway into Q3 2025 including the $20 million first development milestone due from Janssen 2023 Universal Registration Document filed with the French financial market authority and the 2023 Annual Report on Form 20-F filed with the U.S. Securities and Exchange Commission Conference call and webcast scheduled for April 25, 2024 at 8:00 A.M. EDT / 2:00 P.M. |
globenewswire.com |
2024-04-24 20:40:00 |
Czytaj oryginał (ang.) |
| NANOBIOTIX to Announce Fourth Quarter and Full Year 2023 Operational and Financial Update on April 24, 2024 |
Conference call and webcast scheduled for Thursday, April 25, 2024, at 8:00 am EDT / 2:00 pm. CEST Conference call and webcast scheduled for Thursday, April 25, 2024, at 8:00 am EDT / 2:00 pm. CEST |
globenewswire.com |
2024-04-17 20:15:00 |
Czytaj oryginał (ang.) |
| Nanobiotix Announces Completion of Phase 1 Dose Escalation and NBTXR3 Recommended Phase 2 Dose for the Treatment of Inoperable, Recurrent Lung Cancer in Patients Amenable to Re-Irradiation |
PARIS and CAMBRIDGE, Mass., April 02, 2024 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext : NANO –– NASDAQ: NBTX – the ‘‘Company''), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today announced completion of the dose escalation part of a Phase 1 study evaluating potential first-in-class radioenhancer NBTXR3 for patients with non-small cell lung cancer (“NSCLC”) that cannot be treated by surgery (“inoperable”), and has come back (“recurrent”), whom have previously been treated with definitive radiation therapy and are amenable to re-irradiation. The Phase 1 study (“Study 2020-0123”) is being conducted by The University of Texas MD Anderson Cancer Center (“MD Anderson”) as part of an ongoing strategic collaboration with Nanobiotix. |
globenewswire.com |
2024-04-02 20:15:00 |
Czytaj oryginał (ang.) |